Stocktoria
OPKO HEALTH, INC. OPK
OPKO HEALTH, INC. (OPK) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $606.9M at a -37.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.81 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.225 |
| Retained earnings / assets | -1.186 |
| EBIT / assets | -0.061 |
| Equity / liabilities | 1.91 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OPK | OPKO HEALTH, INC. | 4/9 | -0.79 | — | -14.9% |
| INSM | INSMED Inc | 3/9 | -7.47 | — | +66.7% |
| TGTX | TG THERAPEUTICS, INC. | 4/9 | 2.04 | 19.1 | +87.3% |
| CPRX | CATALYST PHARMACEUTICALS, INC. | 4/9 | 14.1 | 18 | +19.8% |
| AXSM | Axsome Therapeutics, Inc. | 4/9 | -5.64 | — | +65.5% |
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
| HCM | HUTCHMED (China) Ltd | 4/9 | 6.45 | 31.3 | -13% |
About OPKO HEALTH, INC.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
FAQ
Is OPK financially healthy?
OPKO HEALTH, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OPK pay a dividend?
No, OPKO HEALTH, INC. does not currently pay a dividend.
How profitable is OPK?
In FY2025, OPKO HEALTH, INC. had a net margin of -37.2% and a return on equity of -17.8%.
What is the analyst price target for OPK?
The average Wall-Street price target for OPKO HEALTH, INC. is $4.38, about 214.7% above the recent price, from 4 analysts (consensus: buy).
Is OPK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on OPKO HEALTH, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.